Clinical Trials
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. announced publication of the BLISS-52 study of Benlysta® (belimumab) in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet. The BLISS-52 study, one of two pivotal...
Clinical Trials
Plexxikon Initiates Phase 1 Clinical Trial for Oral Rheumatoid Arthritis Agent PLX5622
Plexxikon Inc. announced that dosing began in the first of two Phase 1 clinical trials with PLX5622, a novel, oral and highly selective Fms inhibitor, targeted for the treatment of rheumatoid arthritis (RA). PLX5622 has been shown in preclinical...
Clinical Trials
Sanofi-aventis Reports Top-line Results from Phase III Study with BSI-201 in Metastatic Triple-Negative Breast Cancer
Sanofi-aventis and its subsidiary, BiPar Sciences, announced that a randomized Phase III trial evaluating BSI-201 (iniparib*) in patients with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance for co-primary endpoints of overall survival and...
Clinical Trials
Patients enrolled in EU Phase III Clinical Development Progam to evaluate ATX-101 for Reduction of Submental Fat
Bayer HealthCare’s dermatology business Intendis and KYTHERA Biopharmaceuticals, Inc. announced the initiation of two European Phase III studies evaluating ATX-101, a first-in-class injectable adipolytic agent, for the reduction of localized fat under the chin (submental fat). ...
Clinical Trials
VistaGen Therapeutics Announces Successful Completion of Initial Phase 1 Safety Study of AV-101
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company’s novel orally available prodrug candidate for treatment of neuropathic...
Clinical Trials
Gilead Terminates Phase III Clinical Trial of Ambrisentan in Patients with Idiopathic Pulmonary Fibrosis
Gilead Sciences, Inc.announced it is stopping ARTEMIS-IPF, the company's ongoing Phase III clinical trial of ambrisentan in patients with idiopathic pulmonary fibrosis (IPF), due to lack of efficacy. This decision follows an interim analysis...
Clinical Trials
Genentech Phase II study shows Pertuzumab and Herceptin Plus Chemotherapy Significantly Improved the Rate of Complete Tumor
Genentech, a member of the Roche Group announced results from the NEOSPHERE trial, a Phase II neoadjuvant study evaluating the effect of a novel combination regimen of pertuzumab and Herceptin® (trastuzumab) plus chemotherapy (docetaxel) in women with early-stage, HER2-positive...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read